Goldman Sachs
BPMC

Goldman Sachs’s Blueprint Medicines BPMC Stock Holding History

Goldman Sachs’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,100
Closed -$1.57M – 5309
2020
Q2 		$1.57M Sell
20,100
-43,900
-69% -$2.97M ﹤0.01% 3626
2020
Q1 		$3.74M Buy
+64,000
New +$4.12M ﹤0.01% 2862
2019
Q1 		– Sell
-30,000
Closed -$1.62M – 5142
2018
Q4 		$1.62M Buy
+30,000
New +$1.82M ﹤0.01% 3664
2018
Q2 		– Sell
-30,000
Closed -$2.75M – 5666
2018
Q1 		$2.75M Hold
30,000
– – ﹤0.01% 3359
2017
Q4 		$2.26M Buy
+30,000
New +$2.11M ﹤0.01% 3687
2016
Q2 		– Sell
-300,000
Closed -$5.42M – 7027
2016
Q1 		$5.42M Hold
300,000
– – ﹤0.01% 2665
2015
Q4 		$7.9M Buy
+300,000
New +$6.75M ﹤0.01% 2438

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's BPMC Position: Q3 2025 in Review

Goldman Sachs sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 891,287 shares — an estimated $114M sold.

Goldman Sachs first reported a position in BPMC in Q2 2015 and held it in 40 quarters. The position peaked at $114M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Goldman Sachs reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 891,287 Blueprint Medicines shares in Q3 2025, an estimated $114M.
  • Goldman Sachs first reported a position in Blueprint Medicines in Q2 2015 and held it in 40 quarters.
  • Goldman Sachs's Blueprint Medicines position peaked at $114M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.